ArriVent BioPharma, Inc.
AVBP
$29.52
-$0.76-2.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.35M | 8.49M | 6.65M | 6.15M | 5.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.69M | 46.11M | 38.82M | 38.32M | 33.62M |
| Operating Income | -52.69M | -46.11M | -38.82M | -38.32M | -33.62M |
| Income Before Tax | -49.89M | -43.32M | -35.96M | -34.75M | -31.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.89M | -43.32M | -35.96M | -34.75M | -31.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.89M | -43.32M | -35.96M | -34.75M | -31.40M |
| EBIT | -52.69M | -46.11M | -38.82M | -38.32M | -33.62M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.05 | -0.96 | -0.84 | -0.83 | -0.90 |
| Normalized Basic EPS | -0.66 | -0.60 | -0.52 | -0.52 | -0.56 |
| EPS Diluted | -1.05 | -0.96 | -0.84 | -0.83 | -0.90 |
| Normalized Diluted EPS | -0.66 | -0.60 | -0.52 | -0.52 | -0.56 |
| Average Basic Shares Outstanding | 47.61M | 45.07M | 42.94M | 41.91M | 35.01M |
| Average Diluted Shares Outstanding | 47.61M | 45.07M | 42.94M | 41.91M | 35.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |